Document text
Principal Investigator: Vijay Arjun Ramchandani
Organization: NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM
Fiscal Year: 2024
Award: $1,904,646
Funding agency: National Institute on Alcohol Abuse and Alcoholism
I. Intravenous Alcohol Self-Administration (IV-ASA)
The IV-ASA paradigm models the trajectory of an individual’s preferred alcohol exposure in the lab, and is a unique approach to assess binge consumption, i.e., consuming alcohol to BrACs >0.08%, under highly controlled conditions. Binge drinking is associated with a greater risk of negative consequences, and has a major impact on psychological and physical well-being. We have shown that faster rates of alcohol consumption to binge-levels were associated additively with risk factors for AUD, including family history of AUD, male sex, impulsivity, and low level of response to alcohol. Thus, faster binge drinking may be an early indicator of vulnerability to AUD and should be carefully assessed as part of a thorough clinical evaluation. We have also shown that social drinkers with AUD risk factors achieve rates of binge consumption akin to heavy drinkers, and have reported on neuropsychological predictors of binge drinking in young adults. Recently, we published a collaborative study on behavioral and pharmacological correlates of high intensity binge drinking using IV-ASA models and clinical data. The IV-ASA model of binge-consumption can provide unique insights into the biobehavioral mechanisms and heterogeneity of this behavior across the spectrum of use.
II. Understanding neurobiological domains underlying AUD
In collaboration with the Office of the Clinical Director, (PI: Nancy Diazgranados), we have been conducting a deep phenotyping study titled Addictions Neuroclinical Assessment (ANA), to characterize the primary neurofunctional domains of incentive salience, negative emotionality and executive function, using a prospective battery of tasks and questionnaires along with ancillary measures. These domains map onto the 3 stages of the so-called Koobian cycle of addiction: binge-intoxication, preoccupation-anticipation, and withdrawal-negative affect. We recently published findings demonstrating a multi-level factor structure of the domains, with unique features and additional dimensionality that demonstrated cross-correlations among factors such as alcohol motivation, internalizing behaviors, and impulsivity, as well as differentially sensitivity in classifying individuals with and without AUD.
With our IV-ASA paradigms, we have been working on characterizing the pharmacodynamics of alcohol across the neurobiological domains in the ANA framework. Alcohol response phenotypes span a wide and heterogeneous range from subjective effects to objective psychophysiological impairment, and these measures can be broadly categorized into the 3 ANA domains, specifically reward/incentive salience (stimulation, liking, wanting, craving), negative valence (subjective and psychophysiological reactivity to stress-cues), and executive control (loss of control, ability to resist, compulsivity). Our work suggests that the free-access and PR IV-ASA paradigms primarily assess alcohol seeking and consumption, including binge-consumption, driven by the incentive salience and reinforcing properties of alcohol, and can therefore be useful in assessing the underpinnings of alcohol reward. We have completed a study combining IV-ASA with acute stress cues to characterize stress-induced craving and alcohol consumption. We have also developed a human laboratory model of impaired control over alcohol consumption that demonstrated lower ability to resist alcohol for an alternate monetary reward in individuals with impaired control over alcohol. These human lab models provide a unique opportunity to obtain a deeper understanding of the heterogeneity of alcohol response phenotypes across the spectrum of alcohol use and misuse. Our work provides novel and important insights into the critical and essential relationship between alcohol response and AUD risk, and supports the development of novel pharmacological targets for treatment of AUD.
III. Human Laboratory Models in Medication Development for AUD
The laboratory is developing and utilizing human laboratory models to examine the effects of pharmacological agents for the treatment of alcohol use disorder (AUD). These translational studies can complement preclinical studies to screen novel therapeutics that are likely to succeed in clinical trials, thus facilitating future medication development for AUD.
Our prior experimental medicine study examined the effect of varenicline, a (nicotinic) acetylcholine receptor partial agonist approved for smoking cessation, in non-treatment seeking heavy drinkers. This study was reported in previous annual reports and indicated that varenicline could be a targeted treatment for reward-drinking individuals with AUD. This study also exemplified the utility of human laboratory paradigms and the use of fMRI-derived brain biomarkers in medications development for AUD.
Currently, we are analyzing the data from a study examining the effect of the opioid antagonist nalmefene on IV-ASA and neural response to alcohol cues in heavy drinkers. We recently published initial results from the fMRI changes during an fMRI task of reward activation, which showed a significant effect of reward cue type on activation in the nucleus accumbens, but no significant difference between nalmefene and placebo on this response. This study could provide important information about the underlying mechanisms of opioid receptor modulation in alcohol response, and could provide novel data to develop personalized medicine approaches to optimize the therapeutic benefit of nalmefene and other opioid antagonists in the treatment of AUD.
IV. COVID-19 Pandemic Impact on Alcohol and Related Outcomes
Together with the Office of the Clinical Director, we are conducting a longitudinal survey study examining the impact of the COVID-19 pandemic on alcohol use and consequences and related outcomes. This study is being conducting in individuals enrolled in the NIAAA natural history study, leveraging the deep phenotyping assessment and genomic data collected on these individuals prior to the pandemic. Following initial findings reported previously on latent classes of COVID-related stressors and health disparities, in the past year, we have published results of analyses that identified social media addiction as a mediator of the associations between fear of COVID-19, mental health and alcohol use problems. We also found that a history of AUD was associated with greater loneliness which was linked to higher anxiety and depressive symptoms In another analysis, we identified latent classes of positive and negative coping behaviors during the pandemic that were associated with disparate mood symptoms and alcohol-related outcomes. Findings suggested that promoting positive coping strategies could help ameliorate alcohol and mental health problems during public health crises. Finally, we reported novel findings of parosmia and phantosmia that were associated with greater problematic alcohol use and depression, suggesting olfactory deficits in these groups. Additional analyses are underway to examine the trajectory of changes in alcohol use and related consequences in individuals in the post-pandemic phase.
V. Collaborative Studies:
Translational imaging genetics project on the role of nicotinic receptor gene variation and alcohol reward (U01 Co-PI: Mariella De Biasi, UPenn).
Translational imaging genetics project on the role of ZIP8 gene variation and alcohol reward (BtB Co-PI: Mariella De Biasi, UPenn).
Pharmacokinetics and subjective responses to alcohol after bariatric surgery (PI: Marta Yanina Pepino de Gruev, UIUC).
Ketone supplements and alcohol response (PI: Corinde Wiers, UPenn).
Transcriptomic response to alcohol and determinants (PI: Robert Messing, UT Austin).
Terms: <ACh Receptors><Acetylcholine Receptors><Affect><Age><Agonist><Alcohol Chemical Class><Alcohol Drinking><Alcohol abuse><Alcohol consumption><Alcoholic beverage heavy drinker><Alcohols><Algorithms><Annual Reports><Behavior><Behavior assessment><Behavioral><Biological Markers><Brain><Brain Nervous System><COVID-19><COVID-19 pandemic affected><COVID-19 pandemic consequence><COVID-19 pandemic effects><COVID-19 pandemic impact><COVID-19 pandemic impacted><CV-19><Categories><Causality><Cholinergic Receptors><Cholinoceptive Sites><Cholinoceptors><Clampings><Classification><Clinical><Clinical Data><Clinical Evaluation><Clinical Pharmacology><Clinical Testing><Clinical Trials><Closure by clamp><Collaborations><Complement><Complement Proteins><Computer Assisted><Consumption><Coping Behavior><Coping Skills><Coronavirus Infectious Disease 2019><Cues><Data><Development><Dimensions><Disparate><Drug Kinetics><Drugs><Emotional Depression><Encephalon><Enrollment><EtOH abuse><EtOH drinking><EtOH use><Etiology><Face><Family Medical History><Family Medical History Epidemiology><Family history of><Fear><Fright><Functional MRI><Functional Magnetic Resonance Imaging><Future><Genes><Genetic><Goals><Heavy Drinker><Height><Heterogeneity><History><Human><IV Infusion><Image><Impairment><Impulsivity><Individual><Infusion><Infusion procedures><Intoxication><Intravenous><Intravenous infusion procedures><Investigators><Jobs><Ketones><Laboratories><Link><Loneliness><Longitudinal Surveys><Measures><Mediator><Medication><Medicine><Mental Depression><Mental Health><Mental Hygiene><Methodology><Methods><Modeling><Modern Man><Motivation><NIAAA><National Institute on Alcohol Abuse and Alcoholism><Natural History><Negative Valence><Neurobiology><Neuropsychologies><Neuropsychology><Nicotinic Acetylcholine Receptors><Nicotinic Receptors><Nucleus Accumbens><Occupations><Opiate Antagonist><Opiate Receptors><Opiate receptor antagonist><Opioid Antagonist><Opioid Receptor><Opioid receptor antagonist><Outcome><PK/PD><Paraosmias><Perception><Personal Satisfaction><Pharmaceutical Preparations><Pharmacodynamics><Pharmacokinetics><Phase><Phenotype><Physiologic><Physiologic Psychology><Physiological><Physiological Psychology><Placebos><Professional Positions><Property><Psychological Health><Psychophysiological><Psychophysiology><Public Health><Publishing><Questionnaires><Receptor Gene><Recording of previous events><Reporting><Research><Research Personnel><Researchers><Rewards><Risk><Risk Factors><Role><Self Administered><Self Administration><Severities><Sham Treatment><Stimulus><Stress><Structure><System><Systematics><Testing><Therapeutic><Time><Variant><Variation><Weight><Withdrawal><Work><acute stress><addiction><addictive disorder><adult youth><ages><alcohol abuse therapy><alcohol abuse treatment><alcohol co-abuse><alcohol consequences><alcohol cue><alcohol effect><alcohol exposed><alcohol exposure><alcohol ingestion><alcohol intake><alcohol misuse><alcohol problem><alcohol product use><alcohol related cue><alcohol response><alcohol reward><alcohol seeking><alcohol seeking behavior><alcohol treatment><alcohol use><alcohol use disorder><alcoholic beverage consumption><alcoholic drink intake><anxiety symptoms><anxious symptom><bariatric surgery><behavioral assessment><binge alcohol consumption><binge drinking><bio-markers><biobehavior><biobehavioral><biologic marker><biomarker><causation><cease smoking><clinical test><complementation><computer aided><consumption measures><coping strategy><coronavirus disease 2019><coronavirus disease 2019 pandemic consequence><coronavirus disease 2019 pandemic impact><coronavirus disease-19><coronavirus infectious disease-19><craving><depression><depression symptom><depressive><depressive symptoms><developmental><disease causation><disease risk><disorder risk><disparity in health><domain mapping><drinking><drug/agent><effects following the COVID-19 pandemic><emotional functioning><enroll><episodic drinking><ethanol abuse><ethanol consumption><ethanol cue><ethanol drinking><ethanol effect><ethanol exposed><ethanol exposure><ethanol ingestion><ethanol intake><ethanol misuse><ethanol product use><ethanol response><ethanol reward><ethanol seeking><ethanol use><ethanol use disorder><ethanol-seeking behavior><executive control><executive function><exposed to alcohol><exposed to ethanol><exposure to alcohol><exposure to ethanol><fMRI><faces><facial><flexibility><flexible><gastric banding><gastric bypass surgery><genomic data><genomic data-set><genomic dataset><ghrelin><hazardous alcohol use><health disparity><hedonic><histories><image translation><imaging><imaging genetics><impact of the SARS-CoV-2 pandemic><implantable gastric stimulation banding><improved><incentive salience><infusions><insight><inter-individual variability><inter-individual variation><interindividual variability><interindividual variation><intravenous administration><intravenous infusion><lonely><male><mood symptom><nalmefene><negative affect><negative affectivity><neural><neurobiological><neuropsychologic><new drug treatments><new drugs><new pharmacological therapeutic><new therapeutics><new therapy><next generation therapeutics><novel><novel drug treatments><novel drugs><novel pharmaco-therapeutic><novel pharmacological therapeutic><novel therapeutics><novel therapy><obesity surgery><pandemic><pandemic disease><parosmia><personalization of treatment><personalized medicine><personalized therapy><personalized treatment><pharmacokinetic model><pharmacokinetics and pharmacodynamics><pharmacologic><physiopsychology><post-pandemic><pre-clinical study><preclinical study><problem alcohol use><problem drinking><problematic alcohol consumption><problematic alcohol use><prospective><psycho-physiological><psychologic><psychological><quit smoking><research clinical testing><response><response to alcohol><response to ethanol><sex><sham therapy><smoking cessation><social><social media><social role><stomach stapling><stop smoking><stressor><targeted drug therapy><targeted drug treatments><targeted therapeutic><targeted therapeutic agents><targeted therapy><targeted treatment><transcriptomics><translational study><unhealthy alcohol use><varenicline><weight loss surgery><weights><well-being><wellbeing><young adult><young adulthood>